Eli Lilly Releases Results On Latest Disease Modifying Therapeutic For Alzheimer's Disease, Highlighting Need For Cognetivity's CognICA Platform
Eli Lilly Releases Results On Latest Disease Modifying Therapeutic For Alzheimer's Disease, Highlighting Need For Cognetivity's CognICA Platform
礼来公司发布阿尔茨海默氏病最新疾病改善疗法的结果，强调对Cognitivity Cognica平台的需求
The news highlights the urgent need for more consistent, wide scale detection of the disease at an early stage
该消息突出表明，迫切需要在早期阶段对这种疾病进行更一致、更大规模的检测
Vancouver, British Columbia--(Newsfile Corp. - May 9, 2023) - Cognetivity Neurosciences Ltd. (CSE:CGN) (OTCQB:CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity") is pleased to note Eli Lilly & Co.'s results for its experimental drug for Alzheimer's disease, which demonstrated slowing the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval. The drug, donanemab, slowed the disease by 35% over a year and a half in a trial of 1,182 patients with early-stage...
不列颠哥伦比亚省温哥华--（Newsfile Corp.-2023 年 5 月 9 日）- 认知神经科学有限公司 (CSE: CGN) (OTCQB: CGNSF...
登录免费看全文
登录/注册